Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual CD19/CD22 CAR-T for B-cell Non-Hodgkin's Lymphoma
NCT04303247Phase 1Unknown
- Sponsor
- Xinqiao Hospital
- Start
- May 2020
- Primary completion
- May 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19 and CD22 targeted CAR-T cells in B-cell non-Hodgkin lymphoma, sponsored by Xinqiao Hospital. Primary endpoints: The anti-tumor efficiency of CD19 and CD22 targeted CAR-T cells at 4 weeks and The safety evaluation of CD19 and CD22 targeted CAR-T cells at 4 weeks. Status: unknown.
02
Drugs
CD19 and CD22 targeted CAR-T cells
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04303247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04303247.